Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

CSL (CSJ) Stock Price & Analysis

CSJ Stock Chart & Stats

€124.88€0.88(0.71%)
At close: 5:30 PM GMT+1
EUR 75EUR 100EUR 1253 Aug17 Aug28 Aug14 Sep28 Sep12 Oct29 Oct
Day’s Range
EUR 124.74 - EUR 124.88
52-Week Range
EUR 56.00 - EUR 124.88
Previous Close
EUR 124.00
Volume
780
Average Volume (3M)
32
Market Cap
EUR 60.42B
Enterprise Value
EUR 70.67B
Total Cash (Recent Filing)
EUR 1.51B
Total Debt (Recent Filing)
EUR 10.89B
Price to Earnings (P/E)
―
Beta
0.20
Next Earnings
Feb 09, 2027 (Est.)
EPS Estimate
3.59
Next Dividend Ex-Date
N/A
Dividend Yield
1.82%

Bulls Say, Bears Say

Bulls Say

Strong Cash Generation

Positive operating cash flow despite the reported loss demonstrates that CSL’s core businesses continue to convert activity into funding. This supports dividends, buybacks, investment in capacity and product development, while providing resilience through portfolio remediation.

Transformation Savings

Savings delivered ahead of plan can create a durable improvement in the cost base if execution continues. Reinvesting part of those savings into commercial and R&D initiatives may strengthen efficiency while preserving funding for longer-term growth.

Specialty Product Momentum

Growth from recently launched and specialty therapies broadens CSL’s future product base beyond mature franchises. Successful uptake can improve mix and support recurring demand in serious medical conditions, helping offset pressure in challenged products.

Bears Say

Large Impairments And Statutory Loss

The scale of impairments and the statutory loss indicate that previously recorded asset values and earnings expectations have been materially reset. This weakens recent earnings quality, reduces equity support and raises the burden on management to restore returns.

Structural Vifor Decline

Vifor’s challenges reflect durable portfolio and market-access pressures rather than a brief sales fluctuation. Generic competition, lost reimbursement support and the TAVNEOS authorization change can reduce revenue and make recovery dependent on replacement products.

Albumin Market Pressure

The albumin decline shows that pricing and reimbursement pressure in an important market is affecting an established therapy franchise. Continued market-value pressure could constrain revenue quality and margins even if volumes stabilize, limiting recovery in the medium term.

CSL News

CSJ FAQ

What was CSL’s price range in the past 12 months?
CSL lowest stock price was €56.00 and its highest was €124.88 in the past 12 months.
What is CSL’s market cap?
CSL’s market cap is €60.42B.
When is CSL’s upcoming earnings report date?
CSL’s next earnings report is estimated for Feb 09, 2027 (not yet confirmed), which is in 100 days.
How were CSL’s earnings last quarter?
CSL released its earnings results on Aug 17, 2026. The company reported €2.027 earnings per share for the quarter, missing the consensus estimate of €2.112 by -€0.085.
Is CSL overvalued?
According to Wall Street analysts CSL’s price is currently Overvalued.
Does CSL pay dividends?
CSL does not currently pay dividends.
What is CSL’s EPS estimate?
CSL’s EPS estimate is 3.59.
How many shares outstanding does CSL have?
CSL has 479,884,280 shares outstanding.
What happened to CSL’s price movement after its last earnings report?
CSL reported an EPS of €2.027 in its last earnings report, missing expectations of €2.112. Following the earnings report the stock price went up 11.501%.
Which hedge fund is a major shareholder of CSL?
Currently, no hedge funds are holding shares in DE:CSJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology